Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy

被引:148
作者
Borah, A. [1 ]
Raveendran, S. [1 ]
Rochani, A. [1 ]
Maekawa, T. [1 ]
Kumar, D. S. [1 ]
机构
[1] Toyo Univ, Grad Sch Interdisciplinary New Sci, Bio Nano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan
来源
ONCOGENESIS | 2015年 / 4卷
关键词
HEDGEHOG SIGNALING PATHWAY; BETA-CATENIN EXPRESSION; ACUTE MYELOID-LEUKEMIA; EPITHELIAL-MESENCHYMAL TRANSITION; SMALL-MOLECULE INHIBITOR; POLYCOMB-GROUP ONCOGENES; PANCREATIC-CANCER; BREAST-CANCER; PROSTATE-CANCER; TUMOR-GROWTH;
D O I
10.1038/oncsis.2015.35
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy.
引用
收藏
页码:e177 / e177
页数:11
相关论文
共 153 条
  • [81] Prostate cancer stem cells: A new target for therapy
    Maitland, Norman J.
    Collins, Anne T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (17) : 2862 - 2870
  • [82] Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling
    Malanchi, Ilaria
    Peinado, Hector
    Kassen, Deepika
    Hussenet, Thomas
    Metzger, Daniel
    Chambon, Pierre
    Huber, Marcel
    Hohl, Daniel
    Cano, Amparo
    Birchmeier, Walter
    Huelsken, Joerg
    [J]. NATURE, 2008, 452 (7187) : 650 - U12
  • [83] Mesoporous Silica Nanoparticles as Drug Delivery Systems for Targeted Inhibition of Notch Signaling in Cancer
    Mamaeva, Veronika
    Rosenholm, Jessica M.
    Bate-Eya, Laurel Tabe
    Bergman, Lotta
    Peuhu, Emilia
    Duchanoy, Alain
    Fortelius, Lina E.
    Landor, Sebastian
    Toivola, Diana M.
    Linden, Mika
    Sahlgren, Cecilia
    [J]. MOLECULAR THERAPY, 2011, 19 (08) : 1538 - 1546
  • [84] Therapeutic targeting of cancer stem cells
    Maugeri-Sacca, Marcello
    Zeuner, Ann
    De Maria, Ruggero
    [J]. FRONTIERS IN ONCOLOGY, 2011, 1
  • [85] Targeting breast cancer stem cells
    McDermott, Sean P.
    Wicha, Max S.
    [J]. MOLECULAR ONCOLOGY, 2010, 4 (05): : 404 - 419
  • [86] Micchelli CA, 2002, DEVELOPMENT, V129, P843
  • [87] Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346
  • [88] Direct inhibition of the NOTCH transcription factor complex
    Moellering, Raymond E.
    Cornejo, Melanie
    Davis, Tina N.
    Del Bianco, Cristina
    Aster, Jon C.
    Blacklow, Stephen C.
    Kung, Andrew L.
    Gilliland, D. Gary
    Verdine, Gregory L.
    Bradner, James E.
    [J]. NATURE, 2009, 462 (7270) : 182 - U57
  • [89] Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
    Morin, PJ
    Sparks, AB
    Korinek, V
    Barker, N
    Clevers, H
    Vogelstein, B
    Kinzler, KW
    [J]. SCIENCE, 1997, 275 (5307) : 1787 - 1790
  • [90] β-Catenin hits chromatin: regulation of Wnt target gene activation
    Mosimann, Christian
    Hausmann, George
    Basler, Konrad
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009, 10 (04) : 276 - U57